Australian scientists are pioneering a groundbreaking approach to treating triple-negative breast cancer using advanced nanoparticle technology. The innovative research focuses on developing nano-adjuvants that can enhance the immune system's ability to recognize and attack cancer cells. By targeting the tumor microenvironment, these microscopic particles could dramatically improve immunotherapy effectiveness for patients with aggressive cancers. The five-year research project, backed by a significant medical research grant, holds promise for transforming cancer treatment beyond breast cancer.
March 24, 2025
Nanotechnology breakthrough may boost treatment for aggressive breast cancer: Study
"This research will push the boundaries
of science to find innovative treatments" - Alan Rowan, AIBN Director
Researchers in Australia are developing
next-generation nanoparticles to supercharge current treatments for
triple-negative breast cancer (TNBC) -- one of the most aggressive and deadly
forms of the disease.
Key Points
1 Innovative
iron-based nanoparticles designed to boost immune response
2 Targeting
triple-negative breast cancer treatment challenges
3 Research
supported by $3 million medical research grant
4 Potential
applications beyond breast cancer treatment
The researchers are designing innovative
iron-based nanoparticles, or "nano-adjuvants," small enough to fit
thousands on a single strand of hair, to strengthen the body's immune response
against TNBC, according to the University of Queensland's Australian Institute for
Bioengineering and Nanotechnology (AIBN) on Monday, Xinhua news agency
reported.
Unlike other breast cancers, TNBC lacks the
proteins targeted by some of the conventional treatments used against other
cancers, making effective therapy a significant challenge, according to Prof.
Yu Chengzhong from the AIBN.
"Despite the promise of immunotherapy,
its effectiveness against triple-negative breast cancer is extremely limited,
which is leaving too many women without options -- and that's what our research
is trying to change," Yu said.
The nanoparticles are designed to enhance the
activity of T-cells, the white blood cells used by the immune system to fight
disease, within the tumour microenvironment, improving the immune system's
ability to recognise and attack cancer cells, according to Yu.
Supported by a 3 million Australian dollar
($1.89 million) National Health and Medical Research Council grant, the
five-year research project aims to bridge a critical treatment gap, and could
pave the way for clinical applications, not only for TNBC but also for other
hard-to-treat cancers like ovarian cancer.
With over two decades of experience in
nanotechnology and nanomedicine, Yu hopes this breakthrough will transform
cancer treatment by making immunotherapy more effective for patients with
aggressive solid tumours.
"This research will push the boundaries
of science to find innovative treatments that change the way we fight this
cancer, offering hope for women facing devastating outcomes," said AIBN
Director Alan Rowan.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment